Future Directions for JAK Inhibitor Research in Myelofibrosis

While current JAK inhibitors have transformed the management of myelofibrosis, ongoing research is needed to address remaining unmet needs. Future studies could focus on long-term outcomes, including overall survival and disease progression, in broader, more diverse patient populations. Comparative trials between different JAK inhibitors may help clarify optimal sequencing and selection based on patient-specific factors such as anemia, thrombocytopenia, or comorbidities. Investigating combination strategies with emerging targeted therapies or novel agents could enhance disease modification and symptom control. Additionally, real-world studies assessing quality of life, transfusion dependence, and healthcare utilization would provide practical insights for clinicians. Biomarker-driven research may further refine personalized approaches, identifying which patients derive the greatest benefit from specific therapies. Collectively, these studies would help optimize treatment strategies, improve patient outcomes, and expand the therapeutic potential of JAK inhibitors in myelofibrosis.